Skip to contentH
Hepion Pharmaceuticals, Inc.
H
HEPAHepion Pharmaceuticals, Inc. Q4 2021 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$0.00$0.00derived— vs Q4 2020 Net Income-$9.72M-$9.72MderivedN/M vs Q4 2020 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Hepion Pharmaceuticals, Inc. · CIK 1583771 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$8,999,891N/M Operating Cash Flowderived-$7,382,267N/M Free Cash Flowderived-$7,382,266N/M ended Dec 31, 2021 · filed Apr 8, 2022 · 98 d after period end